{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:56:02Z","timestamp":1787061362757,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET\u2019s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for\u2009&gt;\u200950% of all infections. GN pathogens were\u2009~\u20092\u2009\u00d7\u2009as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN\u2009+\u2009GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN\u2009+\u2009GP vHABP (47.8% IET vs. 29.3% non-IET, p\u2009=\u20090.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p\u2009=\u20090.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IET is\u2009~\u20092\u2009\u00d7\u2009more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-022-07755-y","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T03:02:51Z","timestamp":1664938971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012\u20132019"],"prefix":"10.1186","volume":"22","author":[{"given":"Marya D.","family":"Zilberberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Puzniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"issue":"5","key":"7755_CR1","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O\u2019Grady NP, Bartlett JG, Carratal\u00e0 J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of adults with hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"key":"7755_CR2","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198\u2013208.","journal-title":"N Engl J Med"},{"key":"7755_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1164\/rccm.201001-0094OC","volume":"182","author":"M Esperatti","year":"2010","unstructured":"Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A. Nosocomial pneumonia in the Intensive Care Unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182:1533\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"7755_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2020","volume":"29","author":"MS Vallecoccia","year":"2020","unstructured":"Vallecoccia MS, Dominedo C, Cutuli SL, Martin-Loeches I, Torres A, De Pascale G. Is ventilated hospital-acquired pneumonia a worse entity then ventilator-associated pneumonia? Eur Resp Rev. 2020;29: 200023.","journal-title":"Eur Resp Rev"},{"key":"7755_CR5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","volume":"50","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Descriptive epidemiology and outcomes of non-ventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the US, 2012\u20132019. Crit Care Med. 2022;50:460\u20138.","journal-title":"Crit Care Med"},{"key":"7755_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1017\/ice.2021.464","volume":"43","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014\u20132019. Infect Control Hosp Epidemiol. 2022;43:277\u201383.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7755_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000667","volume":"4","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Zilberberg NWD, Shorr AF. Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: a cohort study, United States, 2014\u20132019. Crit Care Explor. 2022;4: e0667.","journal-title":"Crit Care Explor"},{"key":"7755_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13054-015-0795-y","volume":"19","author":"K Marquet","year":"2015","unstructured":"Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.","journal-title":"Crit Care"},{"key":"7755_CR9","unstructured":"US Department of Health and Human Services Office for Human Research Protections. Human Subject Regulations Decision Charts. Available at https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/decision-charts\/index.html; accessed February 3, 2022."},{"key":"7755_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.chest.2018.12.024","volume":"155","author":"MD Zilberberg","year":"2019","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155:1119\u201330.","journal-title":"Chest"},{"key":"7755_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1017\/ice.2018.166","volume":"39","author":"MD Zilberberg","year":"2018","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections. Infect Control Hosp Epidemiol. 2018;39:1112\u20134.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"7755_CR12","doi-asserted-by":"publisher","first-page":"ofz504","DOI":"10.1093\/ofid\/ofz504","volume":"6","author":"MD Zilberberg","year":"2019","unstructured":"Zilberberg MD, Ditch K, Lawrence K, Olesky M, Shorr MD. Carbapenem treatment and outcomes among patients with culture-positive complicated intra-abdominal infections in US hospitals: a retrospective cohort study. Open Forum Infect Dis. 2019;6(12):ofz504. https:\/\/doi.org\/10.1093\/ofid\/ofz504.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"7755_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087382","volume":"9","author":"MB Rothberg","year":"2014","unstructured":"Rothberg MB, Pekow PS, Priya A, Zilberberg MD, Belforti R, Skiest D, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS ONE. 2014;9(1): e87382.","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"7755_CR14","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1086\/677829","volume":"35","author":"MB Rothberg","year":"2014","unstructured":"Rothberg MB, Haessler S, Lagu T, Lindenauer PK, Pekow PS, Priya A, et al. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S107\u201315.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7755_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciz1049","volume":"71","author":"S Haessler","year":"2020","unstructured":"Haessler S, Lindenauer PK, Zilberberg MD, Imrey PB, Yu PC, Higgins T, Deshpande A, Rothberg MB. Blood cultures versus respiratory cultures: 2 different views of pneumonia. Clin Infect Dis. 2020;71:1604\u201312.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"7755_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/BF01712153","volume":"22","author":"F Alvarez-Lerma","year":"1996","unstructured":"Alvarez-Lerma F, ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22(5):387\u201394.","journal-title":"Intensive Care Med"},{"key":"7755_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1378\/chest.122.1.262","volume":"122","author":"M Iregui","year":"2002","unstructured":"Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262\u20138.","journal-title":"Chest"},{"key":"7755_CR18","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","volume":"54","author":"M Paul","year":"2010","unstructured":"Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"7755_CR19","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/cc5036","volume":"10","author":"R Seligman","year":"2006","unstructured":"Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, Teixeira PJ. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10:R125.","journal-title":"Crit Care"},{"key":"7755_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/01.CCM.0000253404.69418.AA","volume":"35","author":"M Leone","year":"2007","unstructured":"Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanese J, Martin C. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007;35:379\u201385.","journal-title":"Crit Care Med"},{"key":"7755_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13054-015-0795-y","volume":"19","author":"K Marquet","year":"2015","unstructured":"Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. incidence and outcomes of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.","journal-title":"Crit Care"},{"key":"7755_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4046\/trd.2021.0018","volume":"84","author":"RE Ko","year":"2021","unstructured":"Ko RE, Min KH, Hong SB, et al. Characteristics, management, and clinical outcomes of patients with hospital acquired and ventilator-associated pneumonia: a multicenter cohort study in Korea. Tuberc Respir Dis. 2021;84:317\u201325.","journal-title":"Tuberc Respir Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07755-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T08:05:06Z","timestamp":1701158706000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7755"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07755-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this study used already existing fully de-identified data, it was exempt from ethics review under US 45 CFR 46.101(b)4 [\n                      \n                      ]. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MDZ\u2019s employer, EviMed Research Group, LLC, has received research grant support from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. BHN\u2019s employer, OptiStatim, LLC, has received support from EviMed Research Group, LLC. LAP is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder in Merck & Co., Inc., Rahway, NJ, USA. RJD is an employee Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder in Merck & Co., Inc., Rahway, NJ, USA. AFS is a consultant to and has received research grant support from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. MDZ and AFS have received grant support and\/or have served as consultants to Spero, Melinta, Tetraphase, Pfizer, Astellas, Shionogi, The Medicines Company, Lungpacer, and Theravance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"775"}}